BioSpace News Archive

Global Coalition for Adaptive Research, the U.S. Sponsor of REMAP-COVID, announced that Eisai has ended the evaluation of eritoran in the REMAP-COVID study.

Gilead Sciences, Inc. was officially recognized as the number one philanthropic funder of HIV-related programs in a new tracking report released by Funders Concerned About AIDS.

On May 19, the Embassy of the Kingdom of the Netherlands presented the 2022 Holland on the Hill Heineken Award to New Jersey-based biopharmaceutical company Merck in a ceremony at the Library of Congress in Washington, D.C. Richard DeLuca, Jr., Executive Vice President of Merck and President of Merck Animal Health, accepted the award on behalf of the company, known as MSD outside the United States and Canada.

Toronto, Ontario--(Newsfile Corp. - May 18, 2022) - Scryb Inc. (CSE: SCYB) (OTCQB: SCYRF) (FSE: EIY) (“Scryb’’ or the “Company”) is pleased to announced that Cybeats has joined Next Generation Manufacturing Canada (NGen)[1], an organization that delivers funding, education, mentorship and development initiatives across Canada.

Pursuant to Article 241-2 of the AMF General Regulations, the purpose of this description is to present the objectives and terms of the share repurchase program of Inventiva S.A. as approved by the Ordinary General Meeting of May 19, 2022.

Akari Therapeutics, Plc presented results from the CASCADE and CORONET studies in patients with COVID-19 pneumonia at the American Thoracic Society 2022 Annual Meeting.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it received notification of Bayer’s intention to end the exclusive worldwide licensing agreement for next-generation mesothelin-directed CAR T-cell therapies.

ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the first quarter ended March 31, 2022 and provided a corporate strategic update.

The global Virtual Clinical Trials market size is estimated to reach around US$ 21.5 billion by 2030 from valued at US$ 8.4 billion in 2020, growing at a CAGR of 6.7% over the forecast period 2021 to 2030.

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), today announced the publication of improved PreTRM® test performance using women from the Proteomic Assessment of Preterm Risk (PAPR) clinical study whose pregnancy outcomes are aligned with updated ACOG gestational age dating guidelines